Effect of Esomeprazole With/Without Acetylsalicylic Acid, Omeprazole and Lansoprazole on Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers
- 527 Downloads
The effect of proton pump inhibitors (PPIs) on the pharmacokinetics and pharmacodynamics of clopidogrel was assessed in two healthy volunteer crossover studies.
Subjects and methods
Study 1: subjects received clopidogrel alone (300-mg loading dose, then 75 mg/day for 28 days) and two of three PPIs (omeprazole 80 mg, esomeprazole 40 mg or lansoprazole 60 mg) plus clopidogrel for 29 days in three treatment periods (randomized treatment sequence assignment). Study 2: subjects received clopidogrel alone (75 mg/day for 9 days) and clopidogrel alone for 4 days followed by clopidogrel plus fixed-combination esomeprazole 20 mg/low-dose acetylsalicylic acid (ASA) 81 mg for 5 days in two treatment periods (randomized treatment sequence assignment). Pharmacokinetic effects were estimated by measuring active metabolite of clopidogrel, and pharmacodynamic effects by inhibition of adenosine diphosphate (ADP)-induced platelet aggregation.
There was a relative decrease of up to 50 % in exposure to the active metabolite of clopidogrel with the different PPIs (study 1), and close to 40 % with esomeprazole/low-dose ASA (study 2), compared with clopidogrel alone. There was an absolute decrease of up to 17 % in inhibition of ADP-induced platelet aggregation with co-administration of different PPIs, compared with clopidogrel alone; however, no differences in platelet inhibition were observed during co-administration with the esomeprazole/low-dose ASA fixed-dose combination.
Omeprazole, esomeprazole and lansoprazole decreased systemic exposure to the active metabolite of clopidogrel in healthy volunteers, leading to modest decreases in its antiplatelet effect. However, no apparent differences in platelet inhibition were observed when esomeprazole was co-administered with low-dose ASA as a fixed-dose combination.
This study was supported by AstraZeneca R&D, Mölndal, Sweden. Medical writing support was provided by Lisa M. Klumpp Callan and Steve Winter of inScience Communications, Springer Healthcare and funded by AstraZeneca.
Conflicts of interest/Disclosure
T. Andersson, P. Nagy, M. Niazi and S. Nylander are employees of AstraZeneca. H. Galbraith and S. Ranjan are employees of Quintiles, who conducted the studies with funding from AstraZeneca. L. Wallentin has received research grants from AstraZeneca.
Study conception, design and monitoring, and interpretation of data: T. Andersson, P. Nagy, M. Niazi, and S. Nylander.
Study design, conduct, analysis and interpretation of data: H. Galbraith and S. Ranjan.
Interpretation of data: L. Wallentin.
All authors contributed to drafting of the article and approved the final version to be published.
- 3.Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205–41. doi: 10.1016/j.jacc.2009.10.015.PubMedCrossRefGoogle Scholar
- 4.Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533–49. doi: 10.1038/ajg.2010.445.PubMedCrossRefGoogle Scholar
- 9.Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez-Perez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–8. doi: 10.1136/gut.2005.080754.PubMedCentralPubMedCrossRefGoogle Scholar
- 15.Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7. doi: 10.1016/S0140-6736(04)16721-4.PubMedCrossRefGoogle Scholar
- 17.Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65–74.PubMedCrossRefGoogle Scholar
- 19.Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304–11. doi: 10.1016/j.jacc.2011.12.024.PubMedCrossRefGoogle Scholar
- 20.Wu J, Jia LT, Shao LM, Chen JM, Zhong DD, Xu S, et al. Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers. Eur J Clin Pharmacol. 2012. doi: 10.1007/s00228-012-1329-z. (Epub ahead of print).
- 23.Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos Biol Fate Chem. 2010;38(1):92–9. doi: 10.1124/dmd.109.029132.PubMedCrossRefGoogle Scholar
- 24.Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81(5):735–41. doi: 10.1038/sj.clpt.6100139.PubMedCrossRefGoogle Scholar
- 28.Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120(23):2322–9. doi: 10.1161/CIRCULATIONAHA.109.873497.PubMedCentralPubMedCrossRefGoogle Scholar
- 31.Harjai KJ, Shenoy C, Orshaw P, Usmani S, Boura J, Mehta RH. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators. Circ Cardiovasc Interv. 2011;4(2):162–70. doi: 10.1161/CIRCINTERVENTIONS.110.958884.PubMedCrossRefGoogle Scholar
- 32.Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123(5):474–82. doi: 10.1161/CIRCULATIONAHA.110.965640.PubMedCrossRefGoogle Scholar
- 35.Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther. 2012;35(1):165–74. doi: 10.1111/j.1365-2036.2011.04890.x.PubMedCrossRefGoogle Scholar
- 37.Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol. 2010;56(5):532–9. doi: 10.1097/FJC.0b013e3181f68209.PubMedCrossRefGoogle Scholar
- 42.Liang Y, Johnston M, Hirsh J, Pare G, Li C, Mehta S, et al. Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. J Thromb Thrombolysis. 2012;34(4):429–36. doi: 10.1007/s11239-012-0762-2.PubMedCrossRefGoogle Scholar
- 43.Ferreiro JL, Ueno M, Tomasello SD, Capodanno D, Desai B, Dharmashankar K, et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circ Cardiovasc Interv. 2011;4(3):273–9. doi: 10.1161/CIRCINTERVENTIONS.110.960997.PubMedCrossRefGoogle Scholar
- 44.Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2012. doi: 10.1016/j.ijcard.2012.03.085. (Epub ahead of print).
- 45.Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients of acute coronary syndrome in Taiwan. Br J Clin Pharmacol. 2012;74(5):824–34. doi: 10.1111/j.1365-2125.2012.04250.x.PubMedCentralPubMedCrossRefGoogle Scholar
- 46.Jaspers Focks J, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome—a systematic review. Heart. 2012. doi: 10.1136/heartjnl-2012-302371. (Epub ahead of print).